Opinion|Videos|July 22, 2024
Recent Data on Bimekizumab for Hidradenitis Suppurativa
Author(s)Vivian Shi, MD, FAAD
Vivian Shi, MD, FAAD, reviews recent phase 3 data on bimekizumab, a biologic therapy for patients with hidradenitis suppurativa.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Bimekizumab is a biologic under investigation for hidradenitis suppurativa (HS). What did recent phase 3 results demonstrate?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol
2
Cardiology Prices Vary Widely by Insurer and State
3
Prior Cancer History Predicts Second Cancers in Polycythemia Vera, Essential Thrombocythemia
4
Hepatitis Prevention Programs Improve Liver Outcomes, but Gaps in Screening, Care Remain
5